- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
EndoSonics to acquire Navius
Intravascular ultrasound developer EndoSonics last month signed an agreement to acquire Navius, a privately held San Diego-based developer of angioplasty balloons, stents, and intravascular radiation devices. The Navius acquisition gives EndoSonics
Intravascular ultrasound developer EndoSonics last month signed an agreement to acquire Navius, a privately held San Diego-based developer of angioplasty balloons, stents, and intravascular radiation devices. The Navius acquisition gives EndoSonics access to the intravascular ultrasound-guided stenting market. EndoSonics has agreed to pay approximately $15.5 million in cash and EndoSonics common stock, in addition to royalties on future product sales. The deal was expected to close July 31.
The Rancho Cordova, CA, firm also announced last month an agreement in principle to partner with Fukuda Denshi, a Japanese medical products company. Fukuda has agreed to make an equity investment and R&D funding totaling $13 million in EndoSonics.
The agreements cut EndoSonics' final ties to Johnson & Johnson's Cordis division, the company's former distributor and therapeutic product partner. EndoSonics decided to terminate its relationship with Cordis when its product orders declined (SCAN 4/29/98).
In other EndoSonics news, the company reported second-quarter 1998 (end-June) net income of $1 million on revenue of $10 million, a 34% increase over the $751,000 net income on revenue of $7.1 million for the previous year's second quarter.
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.
